Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02045056
Other study ID # R01AG042419
Secondary ID
Status Completed
Phase Early Phase 1
First received
Last updated
Start date May 2014
Est. completion date June 2019

Study information

Verified date October 2019
Source University of Kentucky
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to assess the safety and efficacy of gemfibrozil in modulating microRNA-107 levels for the prevention of Alzheimer's disease in subjects with intact cognition and mild cognitive impairment


Description:

Double-blind, placebo controlled, parallel-design. 48 cognitively-intact subjects, and 24 subjects with early cognitive decline (CDR 0.5) will be randomly assigned to treatment with gemfibrozil (600 mg orally twice a day) or placebo for 52 weeks. Safety assessments will include routine assessment of adverse events, safety labs, and brain magnetic resonance imaging.


Recruitment information / eligibility

Status Completed
Enrollment 72
Est. completion date June 2019
Est. primary completion date June 30, 2018
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 65 Years to 90 Years
Eligibility Inclusion Criteria:

Participants must meet all of the following inclusion criteria in order to participate in the study:

1. Men or women aged 65-90, inclusive.

2. Stable medical condition for three months prior to screening visit, with no clinically significant abnormalities of hepatic, renal, and hematologic function defined as follows: Platelets > 100,000, Serum creatinine = 1.6 mg/dL, aspartate aminotransferase (AST) or alanine aminotransferase (ALT) = 1.5 upper limit of normal, No clinically significant abnormalities of other laboratory studies (CBC, chemistry panel)

3. Non-diabetic or well controlled diabetes confirmed by fasting serum glucose <126 mg/dL.

4. Stable medications for 4 weeks prior to screening visit.

5. Physically acceptable for this study as confirmed by medical history, physical exam, neurological exam and clinical tests.

- Exceptions to these criteria may be considered on a case-by-case basis, at the discretion of the Project Director.

Exclusion Criteria:

1. Female participants that are pregnant or of childbearing potential.

2. Unstable medical conditions for three months prior to screening visit such as poorly controlled blood pressure, diabetes, or breathing problems…etc.

3. Clinically significant abnormalities on liver, kidney or other blood tests

4. Significant neurologic disease such as Alzheimer's disease, Parkinson's disease, stroke, brain tumor, multiple sclerosis or seizure disorder.

5. Major depression in past 12 months (DSM-IV criteria), major mental illness such as schizophrenia, or recent (in past 12 months) alcohol or substance abuse.

6. History of invasive cancer within the past two years.

7. Contra-indications to lumbar puncture (bleeding disorder, platelet count < 100,000, anticoagulant treatment, major structural abnormality or sepsis in the area of the lumbosacral spine that would make a lumbar puncture technically difficult).

8. Use of any investigational agents within 30 days prior to screening.

9. Contra-indications to MRI (metallic implants, pacemaker, shrapnel, ect…)

10. Sensitivity, intolerance, or allergies to gemfibrozil or any previous reaction to any cholesterol lowering medicine.

11. Major surgery within eight weeks prior to the Baseline Visit.

12. Blindness, deafness, language difficulties or any other disability which may prevent the potential participant from participating or cooperating in the protocol.

13. Physically unacceptable for this study as confirmed by medical history, physical exam, neurological exam and clinical tests.

- Exceptions to these criteria may be considered on a case-by-case basis, at the discretion of the examining study physician.

Excluded Medications:

1. Experimental drugs

2. Repaglinide

3. "Statins" including but not limited to atorvastatin (Lipitor), fluvastatin (Lescol), lovastatin (Mevacor), pravastatin (Pravachol), rosuvastatin (Crestor), simvastatin (Zocor), or any combination medicines containing these drugs.

4. Coumadin, warfarin, heparin, lovenox, Xarelto, apixaban or other anticoagulants. (Antiplatelet therapy is acceptable).

NOTE: If these drugs are discontinued 4 weeks or more before screening, then the participant can be eligible for the study.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Gemfibrozil

Placebo


Locations

Country Name City State
United States University of Kentucky Lexington Kentucky

Sponsors (1)

Lead Sponsor Collaborator
Gregory Jicha, 323-5550

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Safety Adverse events reported during the course of the trial 52 weeks
Primary microRNA-107 levels MicroRNA-107 levels will be measured in serum and cerebrospinal fluid 48 weeks
Primary beta-amyloid levels Beta-amyloid 1-40 and 1-42 levels will be measured in cerebrospinal fluid at baseline and at 48 weeks 48 weeks
Secondary Free and cued selective reminding test (FCSRT) The FCSRT is a sensitive measure of memory performance that will be measured at baseline and after 48 weeks of gemfibrozil treatment 48 weeks
Secondary Paired associates learning (PAL) The PAL is a sensitive, computerized measure of memory performance that will be measured at baseline and after 48 weeks of gemfibrozil treatment 48 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT06033066 - Financial Incentives and Recruitment to the APT Webstudy N/A
Enrolling by invitation NCT06416072 - Alzheimer's Plasma Extension
Recruiting NCT04851496 - Amyloid Prediction in Early Stage Alzheimer's Disease From Acoustic and Linguistic Patterns of Speech - PAST Extension
Terminated NCT04846426 - Amyloid Prediction in Early Stage Alzheimer's Disease From Acoustic and Linguistic Patterns of Speech - FUTURE Extension
Completed NCT04828122 - Amyloid Prediction in Early Stage Alzheimer's Disease From Acoustic and Linguistic Patterns of Speech
Completed NCT03370744 - Prediction of Cognitive Decline by Neuroimaging Techniques and the Application in Diagnosis and Treatment of Preclinical AD
Completed NCT02963415 - Concurrent Aerobic Exercise and Virtual Reality Cognitive Training N/A
Active, not recruiting NCT04004767 - TRC-PAD Program: In-Clinic Trial-Ready Cohort
Recruiting NCT04468659 - AHEAD 3-45 Study: A Study to Evaluate Efficacy and Safety of Treatment With Lecanemab in Participants With Preclinical Alzheimer's Disease and Elevated Amyloid and Also in Participants With Early Preclinical Alzheimer's Disease and Intermediate Amyloid Phase 3
Recruiting NCT04937959 - Amyloid Prediction in Early Stage Alzheimer's Disease Through Speech Phenotyping - PAST Extension
Completed NCT04928976 - Amyloid Prediction in Early Stage Alzheimer's Disease Through Speech Phenotyping
Terminated NCT04951284 - Amyloid Prediction in Early Stage Alzheimer's Disease Through Speech Phenotyping - FUTURE Extension